Vitreoretinopathy Cell Models for Research

Vitreoretinopathy encompasses a group of rare inherited retinal disorders characterized by abnormal vitreous and retinal development, leading to retinal detachment, cataract, and vision loss. Global prevalence is estimated at 1-9 per 100,000 individuals (Orphanet, 2023). The most common form, Stickler syndrome, affects approximately 1 in 7,500 to 9,000 newborns (NCI, 2023). Risk factors include family history, specific gene mutations (e.g., COL2A1, COL11A1, COL11A2, VCAN), and premature birth for retinopathy of prematurity. Clinical impact includes high risk of retinal detachment (up to 70% in Stickler syndrome by age 20), early-onset cataract, and glaucoma. There is no cure; management focuses on surveillance and surgical intervention. Five-year visual prognosis varies: with timely surgery, 70-90% of eyes retain useful vision; without treatment, progression to blindness is common. Mortality is not directly increased, but quality of life is significantly affected. Research is critical due to limited treatment options and the genetic heterogeneity of the disease.

Vitreoretinopathy is an ideal model for mechanistic studies due to its well-defined genetic subtypes, including Stickler syndrome (COL2A1, COL11A1, COL11A2, COL9A1, COL9A2, COL9A3), Wagner syndrome (VCAN), and Goldmann-Favre syndrome (NR2E3). Public datasets such as ClinVar, gnomAD, and the Retinal Information Network (RetNet) provide mutation spectra. Open questions include the role of extracellular matrix (ECM) proteins in retinal adhesion, the contribution of non-coding variants, and the development of targeted therapies. The disease's monogenic nature facilitates the creation of isogenic cell models to dissect allele-specific effects. Additionally, the eye's immune privilege and accessibility make it amenable to local gene therapy, driving interest in CRISPR-based treatments.

Vitreoretinopathy is not a malignant disease, but its pathogenesis involves key molecular pathways that can be modeled in cancer-like contexts for drug discovery. The major pathways include:

1. Extracellular Matrix (ECM) Remodeling and Collagen Biosynthesis:

• • Mutations in COL2A1, COL11A1, COL11A2, and COL9A1 disrupt type II, IX, and XI collagen networks.
• • Impaired collagen fibril assembly leads to vitreous liquefaction and retinal tears.
• • Downstream effects include activation of TGF-beta signaling, promoting fibrosis.

2. TGF-beta Signaling:

• • TGF-beta superfamily members regulate ECM production and cell differentiation.
• • Dysregulation contributes to epithelial-mesenchymal transition (EMT) in retinal pigment epithelium (RPE).
• • SMAD2/3 phosphorylation is increased in vitreoretinopathy models.

3. Wnt/beta-catenin Pathway:

• • Wnt signaling is critical for retinal development and maintenance.
• • Mutations in VCAN (versican) affect Wnt gradient formation.
• • Aberrant Wnt activation leads to abnormal retinal lamination.

4. Apoptosis and Cellular Stress:

• • Mutant ECM proteins induce endoplasmic reticulum (ER) stress and unfolded protein response (UPR).
• • Activation of ATF4, CHOP, and caspase-12 leads to photoreceptor apoptosis.
• • This pathway is a potential therapeutic target.

Data compiled from ClinVar, COSMIC, and published cohorts (e.g., Stickler syndrome mutation spectrum).

• • TGF-beta/SMAD pathway:
• • Upregulation of TGF-beta1, TGF-beta2, and TGF-beta3 in vitreous.
• • Increased phosphorylation of SMAD2/3.
• • Induction of profibrotic genes (ACTA2, COL1A1, FN1).
• • Wnt/beta-catenin pathway:
• • VCAN mutations impair Wnt ligand sequestration.
• • Beta-catenin accumulation in RPE cells.
• • Activation of target genes (CCND1, MYC).
• • MAPK/ERK pathway:
• • ER stress activates ASK1, leading to JNK and p38 MAPK activation.
• • ERK1/2 phosphorylation promotes cell survival or apoptosis depending on context.
• • PI3K/AKT/mTOR pathway:
• • Activated in response to ECM detachment (anoikis resistance).
• • mTORC1 upregulation increases protein synthesis and ER stress.
• • Apoptotic signaling:
• • BAX/BAK activation, cytochrome c release.
• • Caspase-3 and caspase-9 cleavage.
• • Imbalance between pro- and anti-apoptotic BCL-2 family proteins.

Organoid advantages: Retinal organoids derived from patient iPSCs recapitulate retinal development and disease phenotypes, including ECM abnormalities and photoreceptor degeneration. They provide a 3D environment for studying cell-cell and cell-matrix interactions, and are amenable to CRISPR correction.

• • Col2a1 knockout mouse: Exhibits vitreous abnormalities and retinal detachment; models Stickler syndrome.
• • Col11a1 mutant mouse (chondrodysplasia): Shows vitreoretinal degeneration and hearing loss.
• • Vcan knockout mouse: Displays vitreoretinal degeneration and Wagner syndrome-like phenotype.
• • Nr2e3 mutant mouse (rd7): Models Goldmann-Favre syndrome with enhanced S-cone syndrome.
• • Zebrafish col2a1a mutants: Rapid screening for ECM defects and drug response.
• • Induced models: Injection of collagenase or hyaluronidase into vitreous to mimic liquefaction.
• • PDX: Not applicable as vitreoretinopathy is non-neoplastic; however, patient-derived xenografts of RPE cells can be used.

CRISPR-Cas9 technology enables the creation of isogenic cell lines carrying specific mutations or knockouts. Examples include:

• • COL2A1 knockout ARPE-19: Generated by CRISPR to study ECM instability and TGF-beta activation. Commercially available, sequence-verified models accelerate research.
• • COL2A1 p.Gly1170Ser knock-in: Introduces a common Stickler syndrome mutation into hTERT-RPE1 cells.
• • VCAN knockout HEK293T: For studying versican function in Wnt signaling.
• • NR2E3 knockout iPSC-derived RPE: Models Goldmann-Favre syndrome.

These models are available from commercial sources and are quality-controlled (e.g., validated by Sanger sequencing, off-target analysis). They enable precise mechanistic studies and drug screening without the variability of patient-derived cells.

Knockout and knock-in lines validate gene function in vitreoretinopathy. For example:

• • COL2A1 knockout in ARPE-19 cells confirms its role in collagen secretion and matrix assembly.
• • COL11A1 knock-in of a patient mutation (e.g., p.Gly1036Val) demonstrates dominant-negative effects on collagen fibrillogenesis.
• • VCAN knockout in HEK293T cells reveals its regulation of Wnt/beta-catenin signaling.

These studies use CRISPR screens to identify modifiers and synthetic lethal interactions.

Isogenic pairs (wild-type vs. mutant) enable high-throughput screening for compounds that rescue mutant phenotypes. For example:

• • Screening of FDA-approved drugs in COL2A1 mutant RPE cells to identify chaperones that correct protein folding.
• • Testing of TGF-beta inhibitors (e.g., SB431542) in COL11A1 knockout cells to reduce fibrosis.
• • Resistance modeling: Chronic exposure to ER stress inducers (e.g., tunicamycin) in knockout cells to study adaptive responses.

These screens accelerate lead identification and repurposing.

CRISPR synthetic lethality screens in vitreoretinopathy models identify genetic dependencies. For example:

• • Genome-wide knockout screen in COL2A1 mutant cells to find genes whose loss is lethal only in mutant background.
• • Identification of biomarkers for early detection, such as elevated TGF-beta levels or specific ECM fragments.
• • Use of reporter lines (e.g., TGF-beta luciferase) to monitor pathway activity and discover novel biomarkers.